Cargando…

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms

Menopausal hormone therapy slows bone turnover and reduces the risk of osteoporotic fractures. The objective of this post hoc analysis was to evaluate bone turnover markers (BTM) in the phase 3 REPLENISH trial, which evaluated vasomotor symptoms (VMS) with an oral estradiol/progesterone (E2/P4) in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantine, Ginger, McClung, Michael R, Kagan, Risa, Graham, Shelli, Bernick, Brian, Mirkin, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208564/ http://dx.doi.org/10.1210/jendso/bvaa046.536

Ejemplares similares

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms
por: Santoro, Nanette, et al.
Publicado: (2019)

SAT-001 Clinically Meaningful Effects of E2/P4 Oral Capsule in Treating Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
por: Constantine, Ginger D., et al.
Publicado: (2019)

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
por: Kaunitz, Andrew M., et al.
Publicado: (2020)

SAT-239 Bioidentical Estradiol and Progesterone Improved Hot Flushes, Night Sweats and Sweating
por: Liu, James, et al.
Publicado: (2019)

SAT-LB003 Nonsmokers Benefit from Lower Doses of an Estradiol/Progesterone Combination: Results of the REPLENISH Trial
por: Constantine, Ginger, et al.
Publicado: (2019)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone
por: Mirkin, Sebastian, et al.
Publicado: (2019)

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
por: Constantine, Ginger D., et al.
Publicado: (2020)

SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
por: Liu, James H, et al.
Publicado: (2020)

SAT-219 A Novel 1-Year Contraceptive Vaginal System Delivering Segesterone Acetate and Ethinyl Estradiol: Effects on Lipids and other Hepatic Proteins
por: Archer, David, et al.
Publicado: (2019)

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
por: Kagan, Risa, et al.
Publicado: (2018)

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial
por: Simon, James A., et al.
Publicado: (2017)

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
por: Simon, James A., et al.
Publicado: (2019)

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
por: Lobo, Rogerio A., et al.
Publicado: (2019)

PMON281 PERSISTENT VIRILIZATION AND VASOMOTOR SYMPTOMS IN A TRANSMAN 5-YEARS POST TESTOSTERONE WITHDRAWAL
por: Nemati, Maryam, et al.
Publicado: (2022)

MON-006 Progesterone Receptor Expression in Endometrial Biopsies After 12 Weeks of Exposure to A 4-µg E2 Softgel Vaginal Insert or Placebo
por: Simon, James A, et al.
Publicado: (2020)

Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR
por: Kingsberg, Sheryl A., et al.
Publicado: (2017)

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women
por: Constantine, Ginger D., et al.
Publicado: (2017)

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries
por: Constantine, Ginger D, et al.
Publicado: (2016)

OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)
por: English, Marci, et al.
Publicado: (2022)

SAT-026 Association of Inflammatory Markers with Depressive Symptoms Across the Perinatal Period
por: Braybrook, Emma, et al.
Publicado: (2020)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

SUN-021 Age-Specific Multiples of the Median Level of Serum Anti-Mullerian Hormone Is a Potential Marker for Diagnosis of Polycystic Ovary Syndrome
por: Raymond Li, Hang Wun, et al.
Publicado: (2020)

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
por: Fraser, Graeme, et al.
Publicado: (2019)

SAT-034 The Effect of Natesto on Spermatogenesis, Reproductive Hormones, and Hypogonadal Symptoms. A Phase IV Study
por: Masterson, Thomas A, et al.
Publicado: (2020)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

A Simple Algorithm is Created for Identifying Intermenstrual Intervals Containing an Oscillatory LH Pattern That Associates With Vasomotor Symptoms Using Daily Urinary LH Excretion in the Study of Women’s Health Across the Nation (SWAN)
por: Lasley, Bill L, et al.
Publicado: (2021)

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review
por: Constantine, Ginger D., et al.
Publicado: (2019)

SAT-196 Maternal immunity: Preimplantation Preparation
por: Elbert, Ashleigh, et al.
Publicado: (2019)

SAT-LB042 Effect of Dehydroepiandrosterone on the Perimenopausal Ovary
por: Luna, Selva, et al.
Publicado: (2019)

SAT-233 Management of Pregestational Diabetes Insipidus in Pregnancy
por: Venkataraman, Sandhya, et al.
Publicado: (2019)

SAT-213 Late Diagnosis of Complete Androgen Insensitivity
por: Tsai, Karen, et al.
Publicado: (2019)

SAT-036 Redefining Eunuchoid Body Proportions in Adults
por: Singh, Santosh Kumar
Publicado: (2020)

OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
por: Simon, James, et al.
Publicado: (2020)

SAT-LB1 Detection of Serum Macro-Luteinizing Hormone
por: Ogura-Ochi, Kanako, et al.
Publicado: (2020)

SAT-LB5 Prevalence of Hypogonadism in Young Obese Males
por: Halappanavar, Anup, et al.
Publicado: (2020)

SAT-016 Analytical Performance and Clinical Value of AMH Testing
por: Sluss, Patrick M, et al.
Publicado: (2020)

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial
por: Liu, James H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_35hc5keh0lr1ggp7nk92o2pm17